Followers | 149 |
Posts | 9,339 |
Boards Moderated | 7 |
Alias Born | 03/29/2017 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RCHA huge news out
Rich Pharmaceuticals Retains Experienced Contact Research Organization to Assist with Clinical Trials
10:35 am ET December 5, 2017 (Globe Newswire) Print
Rich Pharmaceuticals, Inc. (OTC PINK: RCHA), a biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, today announced that it has retained IND 2 Results, LLC, (I2R) Atlanta Georgia, to serve as its Contact Research Organization (CRO).
I2R will work on protocol development, medical writing, and regulatory consulting for Rich as it plans to move forward with clinical trials in Hodgkin's Lymphoma (HL). Subsequently, the Company intends to have I2R assist in preparing the protocol for submission to the Food and Drug Administration (FDA).
In addition, I2R is assisting the Company in amending the Acute Myelocytic Leukemia (AML) protocol in preparation for the Submission Package to a major U.S. clinical site soon-to-be-named, and I2R will also prepare submission packages for the clinical site's Institutional Review Board (IRB). In cooperation with the clinical site, and subject to the receipt of adequate additional funding, Rich Pharmaceuticals plans to conduct a study for the treatment of AML in refractory patients in Phase I/II trial. AML is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Because the incidence increases with age, it is expected that incidence will rise as population ages.
"I2R has a strong track record of success in conducting complicated clinical trials. Its multi-disciplinary team of experienced clinical trial professionals will work with Rich Pharmaceuticals as we move forward with our innovative treatment for lymphoma and leukemia," said Ben Chang, Rich Pharmaceuticals CEO. "We believe that getting a talented CRO team on board is an important step for our future."
http://www.ind2results.com/
I'm not trippin over it, I saw level 2. Lot of whacks bringing it down. That buying volume last weeks shows strong hands have shares. First selling day I have seen here. Gonna be chasing if they aren't buying back in.
Glad 2 see they are bringing it 2 a clinic in US. IND2 Is a legit team also. They have quite the impressive team over there.
Awesome news out beer. New trials in the US coming soon.. That is major.
Rich Pharmaceuticals Retains Experienced Contact Research Organization to Assist with Clinical Trials
10:35 am ET December 5, 2017 (Globe Newswire) Print
Rich Pharmaceuticals, Inc. (OTC PINK: RCHA), a biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, today announced that it has retained IND 2 Results, LLC, (I2R) Atlanta Georgia, to serve as its Contact Research Organization (CRO).
I2R will work on protocol development, medical writing, and regulatory consulting for Rich as it plans to move forward with clinical trials in Hodgkin's Lymphoma (HL). Subsequently, the Company intends to have I2R assist in preparing the protocol for submission to the Food and Drug Administration (FDA).
In addition, I2R is assisting the Company in amending the Acute Myelocytic Leukemia (AML) protocol in preparation for the Submission Package to a major U.S. clinical site soon-to-be-named, and I2R will also prepare submission packages for the clinical site's Institutional Review Board (IRB). In cooperation with the clinical site, and subject to the receipt of adequate additional funding, Rich Pharmaceuticals plans to conduct a study for the treatment of AML in refractory patients in Phase I/II trial. AML is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Because the incidence increases with age, it is expected that incidence will rise as population ages.
"I2R has a strong track record of success in conducting complicated clinical trials. Its multi-disciplinary team of experienced clinical trial professionals will work with Rich Pharmaceuticals as we move forward with our innovative treatment for lymphoma and leukemia," said Ben Chang, Rich Pharmaceuticals CEO. "We believe that getting a talented CRO team on board is an important step for our future."
http://www.ind2results.com/
Peeps whacking that bid gonna feel dumb here soon. Legit play here. Major chasing gonna happen.
$MVES news breaks and thisll pop. App in making, several motion pictures in making. Rainbow will be released soon, feature film starring Eric Roberts. $MVES
Glass half full always brother. Good way 2 think. $RCHA
There you go. Ive grabbed myself a heap of $TVOG.
Got no answer
Agreed. Seems they are held up by Bank compliance. I'm thinking we'd get it very very soon.
Awesome info go4. That chart is wicked looking.. Buying volume has been lights out. $TVOG
Yo Cheeky. Looking 4 a good day @ $TGRR.
Haha You are a character my man. $TVOG looking fantastic.
EASY. Dilution faucet was opened and handle broken off.
No toxic 8k which is good, just CEO employment agreement.
Something should be breaking here soon imo.
Nice bro. Still awesome SS. Filings show they had multiple movies they were paying for actors/services with shares so not surprised.
I grabbed up more this last week, baby is due.
That was with uptick of volume. Company told me they would have signed if volume stayed stagnant.
Volume went back 2 crapola and VNDM 4 some reason backed off @ .005.
Regardless, forbearance will lead 2 same conclusion... Id rather see them release PR about new direction and funding.
I agree also.
$TVOG good volume day, might break 1 million. Climbing and climbing.
Turkeys got the ask wall up. Gotta get a PR out here.
JFIL looking good.
JFIL Security Details
Share Structure
Market Value1 $107,614 a/o Dec 01, 2017
Authorized Shares 75,000,000 a/o Dec 01, 2017
Outstanding Shares 18,185,708 a/o Dec 01, 2017
-Restricted 10,754,686 a/o Dec 01, 2017
-Unrestricted 7,431,022 a/o Dec 01, 2017
Held at DTC 6,627,022 a/o Dec 01, 2017
Float 1,827,321 a/o Jul 08, 2016
Par Value 0.001
Transfer Agent(s)
http://www.jubilant-flame.com/
Yes beer. Level 2 looks great, always thin. Heavy volume and this flies.
Nice brother.
Haha yup 2 both. No problem doing that lol.
That's good sign, etrade 2.5 mil block went below VNDM. Reaper might leave, make me eat my words.
IMO need business PR, forbearance is a band aid. They have stopped and gone 2 .005 already.
Id tell peeps not 2 mess with VNDM lol but who knows GL.
Reaper is @ .005. Been there for weeks watching .
TGRR shark on the loose.
Recent company guidance for the company’s first acquisition of (5) bitumen shipping vessels estimated a run rate of over $39,000,000 in annual revenue, and $6,000,000 in EBITDA. Once finalized, Turner, working in conjunction with Network 1 and an expert team of advisors, will begin adding additional ships to the fleet along with targeting the purchasing/leasing of import/export facilities, asphalt refineries, distribution facilities, and related businesses. This will take advantage of estimates that by the year 2018, the combined annual revenue for all bitumen manufacturing facilities in the USA is expected to be over $25 Billion, and worldwide bitumen revenue is expected to reach $100 Billion by the year 2020 as the USA’s infrastructure rebuild expands.
In his most recent statements about the $1 Trillion infrastructure bill, President Trump said, “We will fix it. We will create the first-class infrastructure our country and our people deserve.” President Trump has proposed funding improvements with $200 billion in public funds over 9 years that would leverage $1 trillion in waterfall construction dollars. Infrastructure investment around the world is growing as a result, and Turner is excited to take part in this burgeoning industry.
Steve Helm, Turner CEO stated, “In addition to entering the supply and distribution side of the bitumen industry, the Company is entering the shipping markets at historic lows and plans to execute an aggressive growth strategy to expand from the initial 5 bitumen tankers to up to 30 tanker ships in the next 12-18 months through the investment banking relationship with Network 1.” Expect updated revenue and EBITDA guidance in an upcoming press release along with other company updates as events warrant.
If we get volume run here, this'll run so sick lol. Love me some $TVOG.
Gotta get this QSIM party back on track peeps. Volume has been ramping up lately... Awesome share structure here from what we know.
52-Wk Range
0.0004 - 0.18
Quiet Quiet @ $MVES. PR and some more eyes here needed. Been trying 2 get info from company.
GM $TVOGers. Heres 2 another green day.
Big week coming 4 $TVOG. Should be seeing PR and 8k soon. Just keep climbing stairs here until big pop.
Awesome DD go4. Should have that stickied. Repost it again if youd like and ill get it up there.
Somebody passed math class.
$TVOG has huge plans 4 uplisting tier by tier. However we get there will bring in major money for peeps. Volume pickup shows the ball has begun 2 roll. Just sayin.
Agreed Sunshine. Legit and transparent. $TVOG moving up up.
Waiting on fill in from company. $TGRR looks like its getting ready 2 pop again.
Should be getting close PR and 8k soon per IR peeps. Bring some new eyes and buys here. This baby will keep climbing and climbing.
HALLANDALE BEACH, Fla., Oct. 19, 2017 (GLOBE NEWSWIRE) -- The Movie Studio, Inc. (OTC:MVES) (the "Company") www.TheMovieStudio.com is a vertically integrated motion picture production and distribution company motion pictures, production and distribution assets.
The Movie Studio is pleased to announce that it has successfully negotiated a content license and revenue participation agreement with Lotus Research, Inc. for the Vu-Me on-line content aggregation and application platform. The Movie Studio and Vu-Me App Platform intend to implement an on-line platform and dashboard for "The Movie Studio" with a subscription based credit card interface to access The Movie Studio library and "New Releases" of owned and licensed content available for Video on Demand (VOD) to monetize the content including a back end "bank" In addition to the VOD Platform, The Movie Studio intends to integrate in the acquisition of Emerging Pictures and all of its assets, including its proprietary intellectual property, which includes an innovative technology for a Commercial VOD (Video on Demand) digital delivery platform presently deployed in over 130 theaters, as well as digital distribution rights to potentially many hundreds of films. The technology can also be used to gauge consumer demand as well as provide advanced data analytics to match and deliver content. This enables providers and exhibitors to be more effective and advanced in their distribution tactics and have greater direct contact and feedback from their audiences. The network of over 130 theaters in which the VOD hardware is presently deployed spans 36 states in the U.S.
"With many competing apps available to consumers, Lotus Research opted to leap ahead of the technology wave with several important features," noted Leo Pimentel. These features include: (1) low latency across WiFi and cellular networks; (2) 4K and HD streaming and playback; (3) a proprietary compression algorithm; (4) rapid share-ability across social networking sites and communication channels; (5) machine-learning algorithms to refine and enhance search and content relevance; and (6) effective content tracking across all platforms on and off Vu-Me for robust and accurate reporting and metrics gathering. Leo Pimentel, CEO & Founder, stated today.
About Lotus Research, Inc.: Lotus Research is headquartered in New York City and was founded by Leo Pimentel in 2014. With a mobile-first approach, Lotus Research emphasizes advanced technology, exceptional product design, and immersive user experiences to bring practical and entertaining solutions to market.
"Vu-Me (http://vu.me) is The Movie Studio "APP" that we have always envisioned and when completed, could accelerate The Movie Studio content and business model with a unique platform currently not implemented by any other independent motion picture Company and create unique value propositions for on-line subscribers aligning an APP for Theatrical Releases and subsequent VOD releases, would be a "Netflix for Movie Theaters" ideology with VOD on all your devices. Gordon Scott Venters, President and CEO stated today.
About The Movie Studio Inc.
The Movie Studio, Inc. is a vertically integrated motion picture production and distribution Company with completed motion picture and production assets. The Company acquires, develops, manufactures, and distributes independent motion picture content for worldwide consumption in Theatrical, Video on Demand (VOD), Foreign Sales and on various media devices.
http://www.nasdaq.com/press-release/the-movie-studio-inc-executes-5-year-content-license-and-revenue-participation-agreement-with-lotu-20171019-00936
Thanks bro. Thats what being newly single and having a desk job will do 2 ya lol.